$16.63▴ 0.73%
End-of-day close · 2026-09-01
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
Not enough data yet
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
More coming: dilution / share-count creep.
Fair value
Undervalued
Trading about 31% below our fair-value range
Balance-sheet caution
A cash-flow (DCF) estimate cross-checked against peer multiples.
✦ The read
Viatris Inc.'s earnings-quality signal is not available yet.
Key numbers
Recent news
Sentiment · last 30 days1 article
0 bullish1 neutral0 bearish
Why Pacira BioSciences Skyrocketed Today
Zacks Industry Outlook Highlights Amphastar Pharmaceuticals, Sandoz and Viatris
3 Generic Drug Stocks to Watch Amid Improving Industry Trends
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
Eli Lilly and vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?